Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 8/20 | 0.55 |
| ▸ | RBPJ | Q06330 | 4/20 | 0.55 |
| ▸ | NOTCH3 | Q9UM47 | 4/20 | 0.45 |
| ▸ | OXTR | P30559 | 8/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489381 | 0.97 | NOTCH1 (0.54) | NOTCH1RBPJNOTCH3OXTRKCNH2 | |
| SCHEMBL4492273 | 0.97 | NOTCH1 (0.54) | NOTCH1RBPJNOTCH3OXTRKCNH2 | |
| SCHEMBL4499149 | 0.91 | NOTCH1 (0.68) | NOTCH1RBPJNOTCH3OXTRPSEN1 | |
| SCHEMBL4487355 | 0.90 | NOTCH1 (0.58) | NOTCH1RBPJOXTRKCNH2PSEN1 | |
| SCHEMBL4495015 | 0.90 | PSEN1 (0.54) | NOTCH1RBPJNOTCH3OXTRKCNH2 | |
| SCHEMBL4471835 | 0.90 | NOTCH1 (0.60) | NOTCH1RBPJNOTCH3OXTRKCNH2 | |
| SCHEMBL4495342 | 0.90 | NOTCH1 (0.58) | NOTCH1RBPJNOTCH3OXTRKCNH2 | |
| SCHEMBL4500919 | 0.89 | NOTCH1 (0.55) | NOTCH1RBPJNOTCH3OXTRKCNH2 | |
| SCHEMBL6091894 | 0.89 | NOTCH1 (0.55) | NOTCH1RBPJNOTCH3OXTRKCNH2 | |
| SCHEMBL4493397 | 0.89 | NOTCH1 (0.56) | NOTCH1RBPJNOTCH3OXTRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | claimed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | claimed |
| US-6962913-B2 | Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-08 | — | — | US | claimed |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | claimed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7304056-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304055-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060264417-A1 | Succinoylamino lactams as inhibitors of a-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-11-16 | — | — | US | disclosed |
| US-7101870-B2 | Succinoylamino lactams as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-6962913-B2 | Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-03 | — | — | US | disclosed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264417-A1 | Succinoylamino lactams as inhibitors of a-beta protein production | BACE1, APH1A, APP | NOTCH1 94/4885RBPJ 1902/4885NOTCH3 323/4885 |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | NOTCH1 94/4885RBPJ 1902/4885NOTCH3 323/4885 |
| US-20050245501-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | NOTCH1 94/4885RBPJ 1902/4885NOTCH3 323/4885 |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | NOTCH1 94/4885RBPJ 1902/4885NOTCH3 323/4885 |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | APH1A, BACE1, APP | NOTCH1 125/4885RBPJ 1850/4885NOTCH3 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.